Paratek Patent-Cliff Exposure & CMS Drug Spending Portfolio
Paratek (US): 2 reconciled FDA prescription therapies (80.5% 2025 to 2030 cliff risk), $156.8M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 2 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 80.5% |
| Primary Portfolio LOE Date | 2036-01-01 |
| 2024 CMS Total Public Spend | $156.8M |
| 2024 Medicare Part D Spend | $126.6M |
| 2024 Medicaid Spend | $30.2M |
| California HCAI SB 17 Filings | 9 WAC filings (max 23.5% 2-yr change) |